RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Historical Holders from Q4 2017 to Q1 2025

Symbol
RYTM on Nasdaq
CUSIP
76243J105
Type / Class
Equity / COM
Shares outstanding
61.5M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
64.9M
Holdings value
$3.63B
% of all portfolios
0.007%
Grand Portfolio weight change
0%
Number of holders
204
Number of buys
101
Number of sells
-77
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PRIMECAP MANAGEMENT CO/CA/ 10.69% $348M 6.57M PRIMECAP MANAGEMENT CO/CA/ Dec 31, 2024
GOLDMAN SACHS GROUP INC 3% $96.3M 1.82M THE GOLDMAN SACHS GROUP, INC. Dec 31, 2024

Institutional Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 368K $19.5M +$3.9M $52.97 19
2024 Q4 64.9M $3.63B -$156M $55.98 204
2024 Q3 67.6M $3.54B -$89M $52.39 178
2024 Q2 69.3M $2.85B +$55.5M $41.06 165
2024 Q1 68M $2.94B +$57.2M $43.33 169
2023 Q4 66.7M $3.06B -$32.7M $45.97 164
2023 Q3 68.1M $1.56B +$52.4M $22.93 143
2023 Q2 66.2M $1.09B +$94.9M $16.49 116
2023 Q1 56.6M $1.01B -$50.4M $17.84 124
2022 Q4 62.3M $1.81B +$85.3M $29.12 115
2022 Q3 59.5M $1.45B +$425M $24.50 96
2022 Q2 44.3M $184M -$10.5M $4.15 77
2022 Q1 48.4M $557M +$5.26M $11.52 101
2021 Q4 48.4M $483M -$577K $9.98 89
2021 Q3 47.7M $623M +$5.07M $13.06 92
2021 Q2 47.3M $903M -$4.69M $19.58 100
2021 Q1 47.6M $1.01B +$148M $21.27 121
2020 Q4 40.5M $1.2B +$38.7M $29.73 113
2020 Q3 39.2M $851M -$43.7M $21.67 114
2020 Q2 41.2M $919M +$11.8M $22.30 87
2020 Q1 40.8M $621M -$33.7M $15.22 79
2019 Q4 40M $918M +$205M $22.96 88
2019 Q3 31.2M $674M +$64.8M $21.59 83
2019 Q2 28.2M $620M +$8.6M $22.00 81
2019 Q1 30.9M $846M -$21.9M $27.41 84
2018 Q4 31.7M $851M +$12.8M $26.88 72
2018 Q3 30.3M $885M -$10.3M $29.17 74
2018 Q2 31M $966M +$213M $31.26 84
2018 Q1 20.4M $406M -$5.86M $19.90 52
2017 Q4 21.6M $628M +$507M $29.06 64